Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Quentis Therapeutics Closes $48 Million Series A Financing

Related Content

Which Jobs More Frequently Require Non-Compete Agreements?

FTC Issues Final Rule Prohibiting Most Post-Employment Non-Compete Agreements

Regulation A+ SEC Developments — Recent SEC Enforcement Proceedings and SEC Comment Letter Trends

Current Issues for Qualified Small Business Stock — How New R&E Expensing Rules Could Hurt Your QSBS Status, and Why Cash Management Changes Likely Won’t

A Recap of Resilience: Goodwin’s Life Sciences Practice

The 15-Minute Founder's Guide: Series A Financing Documents

Recent Court Decisions Shed Light on Enforceability of Electronic Contracts in the U.S.

Florida’s Telephone Solicitation Act Survives First Constitutional Challenge

Goodwin Advises Third Arc Bio on Oversubscribed $165 Million Series A Launch

AlmataBio Acquired by Avalo Therapeutics For $22.5 Million

Sionna Therapeutics Completes $182 Million Series C

FogPharma Completes $145 Million Series E Financing

River Closes $40 Million Series B

Reken Closes $10 Million Seed Round

Myrobalan Therapeutics Completes Series A Financing of $24 Million to Develop Potentially First-in-Class CNS Therapeutics with Restorative Potential

Mercy BioAnalytics Raises $41 Million in Series A Financing

Life Sciences

Life Sciences Emerging Companies